(Q38588012)

4 September 2017

Myasthenia gravis: subgroup classification and therapeutic strategies (English)

1 reference

4 September 2017

0 references

1

Nils Erik Gilhus

1 reference

4 September 2017

Jan J Verschuuren

2

1 reference

4 September 2017

1 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

14

1 reference

4 September 2017

10

1 reference

4 September 2017

1023-1036

1 reference

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia and the neuromuscular junction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis and the neuromuscular junction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Guidelines for treatment of autoimmune neuromuscular transmission disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Anti-agrin autoantibodies in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Autoantibodies to agrin in myasthenia gravis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Cortactin autoantibodies in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Seropositive myasthenia gravis: a nationwide epidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis requiring pyridostigmine treatment in a national population cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A systematic review of population based epidemiological studies in Myasthenia Gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Clinical characteristics of pediatric myasthenia: a surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis and risks for comorbidity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Immune-mediated rippling muscle disease: another inflammatory myopathy in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Amyotrophic lateral sclerosis with positive anti-acetylcholine receptor antibodies. Case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Left ventricular long-axis function in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Autoimmune targets of heart and skeletal muscles in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Serial measurements of cardiac troponin I in patients with myasthenia gravis-related cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Overlooked non-motor symptoms in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A genome-wide association study of myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Muscle specific kinase autoimmune myasthenia gravis in children: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Association of HLA-DRB1∗14, -DRB1∗16 and -DQB1∗05 with MuSK-myasthenia gravis in patients from Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

The search for new antigenic targets in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

EFNS/ENS Guidelines for the treatment of ocular myasthenia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Acetylcholinesterase inhibitor treatment for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

CORTICOTROPIN IN TREATMENT OF OCULAR MYASTHENIA; A CONTROLLED CLINICAL TRIAL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Alternate-day prednisone: preliminary report of a double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A clinical therapeutic trial of cyclosporine in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Phase II trial of methotrexate in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Comparison of IVIg and PLEX in patients with myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Immunosuppressive agents for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Medical and surgical treatment for ocular myasthenia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Fracture rate in patients with myasthenia gravis: the general practice research database.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Inhibition of GTPase Rac1 in endothelium by 6-mercaptopurine results in immunosuppression in nonimmune cells: new target for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Use and monitoring of low dose rituximab in myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Long-lasting treatment effect of rituximab in MuSK myasthenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Thymectomy for non-thymomatous myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Video-assisted thoracoscopic surgery versus robotic-assisted thoracoscopic surgery in the surgical treatment of Masaoka stage I thymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Update on juvenile myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Plasma exchange for myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Comparative analysis of therapeutic options used for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Neuromuscular disease: acute treatment for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Intravenous immunoglobulin for myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis: management issues during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Arthrogryposis multiplexa congenita: an epidemiologic study of nearly 9 million births in 24 EUROCAT registers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Myasthenia gravis associated with etanercept therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

The road not taken: antigen-specific therapy and neuroinflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900145-3

7 January 2021

10.1016/S1474-4422(15)00145-3

Identifiers

DOI

1 reference

release_l3ef6tivgfb3vmbzf25mgcoika

4 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l3ef6tivgfb3vmbzf25mgcoika

24 November 2022

mapped directly with Wikidata item

PubMed ID

26376969

1 reference

PubMed ID

26376969